自膨胀生物瓣膜经导管主动脉瓣置换术后8年临床结局与性能
8年全因死亡78.3%,但存活者心功能持续改善,79.3%仍为NYHA≤II级,平均跨瓣压差和瓣周漏无显著变化,中重度结构性瓣膜 deterioration 和晚期生物瓣衰败发生率低。
要点
- 8年全因死亡率78.3%,但存活者心功能持续改善。
- 平均跨瓣压差和瓣周漏在长期随访中保持稳定。
- 8年中重度SVD和晚期BVF累积发生率较低。
核心结论
- CoreValve第一代自膨胀生物瓣膜TAVR后8年随访显示令人安心的长期性能和耐久性证据。
主要发现
- 8年随访内728例死亡,Kaplan-Meier曲线分析全因死亡率为78.3%。
- 8年时79.3%的存活患者仍为NYHA心功能≤II级。
- 平均跨瓣压差出院时9±4 mmHg,8年时9±5 mmHg,P=0.495。
- 配对分析显示瓣周漏0/1级比例从术后至随访≥5年无显著变化(P=0.164)。
- 8年累积发生率:中度SVD 3.0%(95%CI 2.1-4.3%),重度SVD 1.6%(95%CI 0.6-3.9%),晚期BVF 2.5%(95%CI 1.2-5%)。
关键数值与推荐
- SVD和晚期BVF根据2017年EAPCI/ESC/EACTS标准的修改版定义。
临床怎么用
- 对于不能手术或高危的重度症状性主动脉瓣狭窄患者,CoreValve自膨胀瓣膜TAVR可提供持续的临床和血流动力学获益。
- 长期随访中需关注结构性瓣膜 deterioration 和生物瓣衰败,但发生率较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: In the last decade, transcatheter aortic valve (TAV) replacement determined a paradigm shift in the treatment of patients with severe symptomatic aortic stenosis. Data on long-term TAV performance are still limited. We sought to evaluate the clinical and haemodynamic outcomes of the CoreValve self-expandable valve up to 8-year follow-up (FU). METHODS AND RESULTS: Nine hundred and ninety inoperable or high-risk patients were treated with the CoreValve TAV in eight Italian Centres from June 2007 to December 2011. The median FU was 4.4 years (interquartile range 1.4-6.7 years). Longest FU reached 11 years. A total of 728 died within 8-year FU (78.3% mortality from Kaplan-Meier curve analysis). A significant functional improvement was observed in the majority of patients and maintained over time, with 79.3% of surviving patients still classified New York Heart Association class ≤ II at 8 years. Echocardiographic data showed that the mean transprosthetic aortic gradient remained substantially unchanged (9 ± 4 mmHg at discharge, 9 ± 5 mmHg at 8 years, P = 0.495). The rate of Grade 0/1 paravalvular leak was consistent during FU with no significant change from post-procedure to FU ≥5 years in paired analysis (P = 0.164). Structural valve deterioration (SVD) and late bioprosthetic valve failure (BVF) were defined according to a modification of the 2017 EAPCI/ESC/EACTS criteria. In cumulative incidence functions at 8 years, moderate and severe SVD were 3.0% [95% confidence interval (CI) 2.1-4.3%] and 1.6% (95% CI 0.6-3.9%), respectively, while late BVF was 2.5% (95% CI 1.2-5%). CONCLUSION: While TAVs are questioned about long-term performance and durability, the results of the present research provide reassuring 8-year evidence on the CoreValve first-generation self-expandable bioprosthesis.
引用
- Testa L, Latib A, Brambilla N, et al. Long-term clinical outcome and performance of transcatheter aortic valve replacement with a self-expandable bioprosthesis. Eur Heart J. 2020. PMID: 31904800. doi:10.1093/eurheartj/ehz925
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。